In recent years, immune checkpoint inhibitors have had great success in the treatment of advanced cancers, but often, they are only effective in a minority of patients. Researchers from Weill Cornell Medicine have discovered that the activation of the pentose phosphate pathway (PPP) in combination with standard immune checkpoint inhibitors resulted in enhanced antitumor efficacy both in vitro and in vivo.